Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
Advertisement
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
This orally available, selective inhibitor of XPO1 is the first agent of its kind to receive commercialization approval.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
With insights into next-generation therapies, this discussion explores what’s ahead in the follicular lymphoma landscape.
Ruemu Birhiray, MD of Hematology Oncology of Indiana leads the continuation of a roundtable discussion on FL treatment.
Three experts analyze data on combination therapy for FL, including efficacy, safety, and strategy adoption.
Advertisement
Clinical evaluations of this bispecific antibody as monotherapy or in polytherapy for B-cell non-Hodgkin lymphomas continue.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
CAR22 therapy demonstrated an ORR of 100% and a complete response rate of 83% in six patients with MCL or FL.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
In the TRANSCEND FL trial liso-cel has met primary and secondary endpoints for both MZL and FL with manageable safety.
The positive opinion is based on results from the phase II TRANSCEND FL study, in which liso-cel showed an ORR of 97.1%.
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Elizabeth Brem, MD provides valuable insights for clinicians and researchers focused on advancing care in FL.
Relmacabtagene autoleucel is an anti-CD19 chimeric antigen receptor T-cell product
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
The 5-year follow-up analysis of ZUMA-5 showed continued efficacy and no new safety signals.
Data support rituximab over watchful waiting in front-line therapy for low-tumor-burden follicular lymphoma, study concludes.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.